Skip to main content
Premium Trial:

Request an Annual Quote

Simulations Plus Reports $3M in Preliminary Q3 Revenues

Premium

Simulations Plus today reported preliminary revenues for its third fiscal quarter of $3.1 million — a nearly 15 percent increase over the prior-year period and the first quarter in which the firm generated more than $3 million in revenue.

For the three-month period ended May 31, preliminary revenues for the company's pharmaceutical software and services business increased 17 percent year-over-year to $2.3 million, while revenues for its Words+ subsidiary rose 9 percent to $794,000.

Simulations Plus said that it expects to file its quarterly report with the US Securities and Exchange Commission and release its final earnings statement in mid-July.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more